Traders bought shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading hours on Thursday. $63.20 million flowed into the stock on the tick-up and $43.04 million flowed out of the stock on the tick-down, for a money net flow of $20.16 million into the stock. Of all companies tracked, Eli Lilly and had the 22nd highest net in-flow for the day. Eli Lilly and traded down ($0.70) for the day and closed at $79.32

A number of research firms have issued reports on LLY. Leerink Swann reissued a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. Morgan Stanley reaffirmed a “hold” rating and issued a $88.00 target price on shares of Eli Lilly and in a research report on Saturday, June 4th. Vetr downgraded Eli Lilly and from a “strong-buy” rating to a “buy” rating and set a $85.08 target price for the company. in a research report on Monday, April 18th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Eli Lilly and in a research report on Sunday, March 27th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research report on Friday, May 13th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Buy” and a consensus target price of $94.86.

The stock has a 50-day moving average price of $75.26 and a 200 day moving average price of $76.19. The firm has a market capitalization of $84.07 billion and a price-to-earnings ratio of 36.55.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 26th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.85 by $0.02. During the same quarter in the prior year, the company posted $0.87 earnings per share. The firm earned $4.87 billion during the quarter, compared to the consensus estimate of $4.82 billion. The business’s revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Co. will post $3.57 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Stockholders of record on Monday, August 15th will be given a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 2.57%. The ex-dividend date is Thursday, August 11th.

In related news, CAO Donald A. Zakrowski sold 1,600 shares of Eli Lilly and stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $75.86, for a total transaction of $121,376.00. Following the sale, the chief accounting officer now directly owns 3,113 shares of the company’s stock, valued at $236,152.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 12,000 shares of Eli Lilly and stock in a transaction dated Wednesday, April 27th. The stock was sold at an average price of $76.27, for a total value of $915,240.00. Following the sale, the senior vice president now directly owns 45,101 shares in the company, valued at $3,439,853.27. The disclosure for this sale can be found here.

A number of large investors have recently added to or reduced their stakes in LLY. Dimensional Fund Advisors LP increased its stake in Eli Lilly and by 7.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,488,271 shares of the company’s stock worth $125,422,000 after buying an additional 105,381 shares during the period. BNP Paribas Arbitrage SA increased its stake in Eli Lilly and by 81.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 272,917 shares of the company’s stock worth $22,996,000 after buying an additional 122,779 shares during the period. Dorsey & Whitney Trust CO LLC increased its stake in Eli Lilly and by 1.2% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 20,579 shares of the company’s stock worth $1,734,000 after buying an additional 239 shares during the period. Stephens Inc. AR increased its stake in Eli Lilly and by 10.7% in the fourth quarter. Stephens Inc. AR now owns 35,447 shares of the company’s stock worth $2,987,000 after buying an additional 3,426 shares during the period. Finally, I.G. Investment Management LTD. increased its stake in Eli Lilly and by 21.4% in the fourth quarter. I.G. Investment Management LTD. now owns 299,426 shares of the company’s stock worth $25,230,000 after buying an additional 52,713 shares during the period.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.